Ikena Oncology Stock Market Value
| IKNA Stock | USD 1.49 0.04 2.61% |
| Symbol | Ikena |
Ikena Oncology Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ikena Oncology. If investors know Ikena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ikena Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.23) | Revenue Per Share | Quarterly Revenue Growth (0.88) | Return On Assets | Return On Equity |
The market value of Ikena Oncology is measured differently than its book value, which is the value of Ikena that is recorded on the company's balance sheet. Investors also form their own opinion of Ikena Oncology's value that differs from its market value or its book value, called intrinsic value, which is Ikena Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ikena Oncology's market value can be influenced by many factors that don't directly affect Ikena Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ikena Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ikena Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ikena Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Ikena Oncology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Ikena Oncology's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Ikena Oncology.
| 01/17/2025 |
| 02/16/2025 |
If you would invest 0.00 in Ikena Oncology on January 17, 2025 and sell it all today you would earn a total of 0.00 from holding Ikena Oncology or generate 0.0% return on investment in Ikena Oncology over 30 days. Ikena Oncology is related to or competes with Edgewise Therapeutics, Design Therapeutics, Xilio Development, Monte Rosa, Werewolf Therapeutics, Stoke Therapeutics, and Anebulo Pharmaceuticals. Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient... More
Ikena Oncology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Ikena Oncology's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Ikena Oncology upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.1) | |||
| Maximum Drawdown | 16.13 | |||
| Value At Risk | (3.38) | |||
| Potential Upside | 3.87 |
Ikena Oncology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ikena Oncology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Ikena Oncology's standard deviation. In reality, there are many statistical measures that can use Ikena Oncology historical prices to predict the future Ikena Oncology's volatility.| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.24) | |||
| Total Risk Alpha | (0.24) | |||
| Treynor Ratio | (0.35) |
Ikena Oncology Backtested Returns
Ikena Oncology holds Efficiency (Sharpe) Ratio of -0.0685, which attests that the entity had a -0.0685 % return per unit of risk over the last 3 months. Ikena Oncology exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Ikena Oncology's Standard Deviation of 2.36, risk adjusted performance of (0.06), and Market Risk Adjusted Performance of (0.34) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 0.66, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Ikena Oncology's returns are expected to increase less than the market. However, during the bear market, the loss of holding Ikena Oncology is expected to be smaller as well. At this point, Ikena Oncology has a negative expected return of -0.17%. Please make sure to check out Ikena Oncology's skewness, day typical price, and the relationship between the maximum drawdown and daily balance of power , to decide if Ikena Oncology performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.44 |
Modest reverse predictability
Ikena Oncology has modest reverse predictability. Overlapping area represents the amount of predictability between Ikena Oncology time series from 17th of January 2025 to 1st of February 2025 and 1st of February 2025 to 16th of February 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Ikena Oncology price movement. The serial correlation of -0.44 indicates that just about 44.0% of current Ikena Oncology price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.44 | |
| Spearman Rank Test | -0.05 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Ikena Oncology lagged returns against current returns
Autocorrelation, which is Ikena Oncology stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Ikena Oncology's stock expected returns. We can calculate the autocorrelation of Ikena Oncology returns to help us make a trade decision. For example, suppose you find that Ikena Oncology has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Ikena Oncology regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Ikena Oncology stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Ikena Oncology stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Ikena Oncology stock over time.
Current vs Lagged Prices |
| Timeline |
Ikena Oncology Lagged Returns
When evaluating Ikena Oncology's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Ikena Oncology stock have on its future price. Ikena Oncology autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Ikena Oncology autocorrelation shows the relationship between Ikena Oncology stock current value and its past values and can show if there is a momentum factor associated with investing in Ikena Oncology.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ikena Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ikena Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ikena Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ikena Oncology Stock:Check out Ikena Oncology Correlation, Ikena Oncology Volatility and Ikena Oncology Alpha and Beta module to complement your research on Ikena Oncology. For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Ikena Oncology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.